Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Exclusion Criteria

• •If the patient has brain metastasis, they must have stable neurologic status without the use of steroids or on a stable or decreasing dose of steroids
• •Presence of clinically significant gastrointestinal abnormalities that may affect the absorption of study treatments
• •A medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the Investigator
• •Patient has a concomitant cardiovascular issue that precludes adequate study treatment compliance or increases patient risk
• •Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
• •Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study
• •Prior anti-cancer monoclonal antibody within 4 weeks prior to baseline
• •Currently enrolled in another investigational study
• •Has disease that is suitable for approved therapy administered with curative intent